exemestane

Known as: Exemestano, exemestane [Chemical/Ingredient], examestane 
A drug used to treat advanced breast cancer and to prevent recurrent breast cancer in postmenopausal women who have already been treated with… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
BACKGROUND Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE Entinostat is an oral isoform selective histone deacetylase inhibitor that targets resistance to hormonal therapies in… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin… (More)
  • table 1
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE Tremelimumab is a fully human monoclonal antibody specific for CTL-associated antigen 4 (CTLA4) with single-agent… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE To evaluate the influence of adjuvant tamoxifen and exemestane on cognitive functioning in postmenopausal patients with… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Patients with early-stage, hormone receptor-positive breast cancer have considerable residual risk for recurrence after… (More)
  • figure 1
  • table 1
  • figure 4
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND Early improvements in disease-free survival have been noted when an aromatase inhibitor is given either instead of or… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND Tamoxifen preserves bone in postmenopausal women, but non-steroidal aromatase inhibitors accelerate bone loss and… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Tamoxifen, taken for five years, is the standard adjuvant treatment for postmenopausal women with primary, estrogen… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?